Quantcast
30.1 C
United States of America
Tuesday, August 3, 2021

What Do You Think of the New Alzheimer's Drug Approval?

Must read

What Do You Think of the New Alzheimer's Drug Approval?

Amid significant controversy, the US Food and Drug Administration (FDA) last week approved the antiamyloid agent aducanumab (Aduhelm) for the treatment of Alzheimer’s disease, disregarding the recommendation by its own advisory panel not to approve the drug.

Advisory committee members had voted eight to one against approving the drug because they felt there was insufficient evidence of efficacy from clinical trials involving patients with early Alzheimer’s disease. Two other members said they were uncertain regarding efficacy. Multiple panel members have resigned in protest after the approval was announced.

As a condition of approval, the FDA is requiring Biogen to conduct a new randomized, controlled clinical trial to verify the drug’s clinical benefit. The agency can withdraw its approval if the drug fails to show clinical benefit in this trial.

- Advertisement -

If you would be willing to speak to a reporter from Medscape or STAT, please fill out this Google form.

Author:
This post originally appeared on Medscape Medical News Headlines

- Advertisement -
What Do You Think of the New Alzheimer's Drug Approval?
Newslanes Mediahttps://newslanes.com
Newslanes.com is the leading e-news platform for the latest breaking news of world today. We aggregate and gather popular stories, business news, tech releases and much more. The news repository targets everyone after factual and well-researched information from a dedicated global team of news reporters and editors.
- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisement -

Latest article